HUTCHMED will announce its 2025 final results on March 5, 2026, with webcasts for analysis and Q&A.
Quiver AI Summary
HUTCHMED (China) Limited has announced it will release its final results for the year ending December 31, 2025, on March 5, 2026, at 6:00 am EST. Following the release, the company will host two webcast presentations for analysts and investors, one in English at 8:00 am EST and one in Chinese at 8:30 am HKT on March 6. Both webcasts will be available live on the company's website, where a replay and presentation downloads will also be accessible shortly after the events. HUTCHMED, a biopharmaceutical company, focuses on developing targeted therapies and immunotherapies for cancer and immunological diseases, with its products marketed in China and other global regions. For further details, interested parties can visit their website or contact the company directly.
Potential Positives
- HUTCHMED will announce its final results for 2025 on March 5, 2026, indicating transparency and engagement with stakeholders.
- The company is hosting two webcasts for stakeholders, demonstrating its commitment to communication and investor relations.
- HUTCHMED’s status as a commercial-stage biopharmaceutical company reflects its progress in bringing innovative therapies to market.
Potential Negatives
- The announcement of the final results is set for March 5, 2026, which may indicate that the reporting timeline is later than expected or industry standards, potentially causing concerns about the company's financial performance.
- The need for two separate webcasts for English and Chinese audiences suggests a complex communication strategy that may dilute clarity for global investors and analysts.
- None
FAQ
When will HUTCHMED announce its final results for 2025?
HUTCHMED will announce its final results on March 5, 2026, at 6:00 am EST.
What webcasts will HUTCHMED host following the results announcement?
HUTCHMED will host an English webcast on March 5, 2026, at 8:00 am EST and a Chinese webcast at 8:30 am HKT on March 6, 2026.
How can I access the HUTCHMED webcasts?
The webcasts can be accessed live on HUTCHMED's website at www.hutch-med.com/event/.
Will a replay of the webcasts be available?
Yes, a replay will be available on HUTCHMED's website shortly after the events conclude.
What is HUTCHMED's focus as a biopharmaceutical company?
HUTCHMED is focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$HCM Hedge Fund Activity
We have seen 22 institutional investors add shares of $HCM stock to their portfolio, and 32 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GOLDMAN SACHS GROUP INC removed 289,135 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $4,553,876
- JANE STREET GROUP, LLC added 164,378 shares (+93.4%) to their portfolio in Q3 2025, for an estimated $2,588,953
- SCHRODER INVESTMENT MANAGEMENT GROUP removed 112,220 shares (-4.4%) from their portfolio in Q3 2025, for an estimated $1,767,465
- CATALYST FUNDS MANAGEMENT PTY LTD removed 109,845 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,730,058
- GTS SECURITIES LLC added 82,132 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,293,579
- UBS GROUP AG removed 76,240 shares (-55.6%) from their portfolio in Q4 2025, for an estimated $1,016,279
- AMUNDI added 65,898 shares (+41.9%) to their portfolio in Q3 2025, for an estimated $1,037,893
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$HCM Analyst Ratings
Wall Street analysts have issued reports on $HCM in the last several months. We have seen 0 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Underweight" rating on 09/22/2025
To track analyst ratings and price targets for $HCM, check out Quiver Quantitative's $HCM forecast page.
Full Release
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Feb. 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its final results for the year ended December 31, 2025 on Thursday, March 5, 2026 at 6:00 am Eastern Standard Time (EST) / 11:00 am Greenwich Mean Time (GMT) / 7:00 pm Hong Kong Time (HKT).
HUTCHMED management will host two webcast presentations for analysts and investors to discuss the final results, followed by Q&A sessions. The English webcast will be held on Thursday, March 5, 2026, at 8:00 am EST (1:00 pm GMT / 9:00 pm HKT). The Chinese (Putonghua) webcast will be held at 8:30 am HKT / 12:30 am GMT on Friday, March 6, 2026 (7:30 pm EST on Thursday, March 5, 2026).
Both webcasts will be available live via the website of the Company at www.hutch-med.com/event/ . The presentation will be available to download shortly before the webcast begins. A replay will also be available on the website shortly after the event.
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn .
CONTACTS
| Investor Enquiries | +852 2121 8200 / [email protected] |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / [email protected] |
| Ben Atwell / Tim Stamper | +44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / [email protected] |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Freddie Barnfield / Jeffrey Wong / Duncan Monteith | +44 20 7260 1000 |
